DaVita NYSE: DVA
DaVita Inc., formerly DaVita HealthCare Partners Inc., operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG).
Name | DaVita |
Ticker | DVA |
Exchange | NYSE |
Sector | Health Care |
Industry | Kidney Failure |
Price
52W Low/High |
107.46
72.41 / 123.89 |
Momentum | Neutral |
Market cap | 12 B |
1Y Total Return |
39.89%
Below Average |
1Y Volatility |
31.50%
Less Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
DaVita Inc., formerly DaVita HealthCare Partners Inc., operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG).
Details
Ticker | DVA |
Name | DaVita |
ISIN | US23918K1088 |
CUSIP | 23918K108 |
Exchange | NYSE |
Sector | Health Care |
Industry | Kidney Failure |
Country | USA |
Currency | U.S. Dollar |
Share as of 4/13/21
Close Price | 107.46 |
52W Low/High | 72.41 / 123.89 |
Market cap | 12 B |
1Y Total Return |
39.89%
Below Average |
1Y Volatility |
31.50%
Less Risk |
Beta | 1.54 |
PE (trailing) |
17.03
Below Average |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | 6.7% |
Cash from Op. / Cur. Liabilities | 0.80 |
Diluted Earnings / Share | 6.31 |
ROE | 44.0% |
ROIC | 7.1% |
Price / Revenue | 1.1 |
Price / Book | 9.5 |
Price / CF | 6.7 |
Current Ratio | 1.3 |
Cur.Liabilities / Tot.Liabilities | 0.2 |
Financial Leverage | 8.09 |
in Mils USD |
rolling-year up to December
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
11,551
|
11,388
|
11,405
|
10,877
|
10,707
|
9,982
|
|
Gross Profit |
3,562
|
3,474
|
3,209
|
3,237
|
3,276
|
3,126
|
|
R&D |
0
|
0
|
0
|
0
|
0
|
0
|
|
EBITDA |
2,022
|
2,150
|
1,496
|
2,196
|
2,446
|
1,524
|
|
Operating Income |
1,668
|
1,631
|
1,530
|
1,821
|
2,013
|
1,123
|
|
Net Income exc. Extra |
774
|
811
|
159
|
664
|
880
|
270
|
|
per Share | |||||||
Diluted avg Shares |
123
|
154
|
172
|
191
|
205
|
216
|
|
EPS exc. Extra |
6.31
|
5.27
|
0.92
|
3.47
|
4.29
|
1.25
|
|
Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
16,989
|
17,311
|
19,110
|
18,975
|
18,756
|
18,515
|
|
Cash, Eq & Invt ShortTerm |
522
|
1,220
|
418
|
552
|
982
|
1,907
|
|
Total Current Assets |
3,149
|
3,690
|
8,424
|
8,771
|
3,995
|
4,503
|
|
Total Non-Current Assets |
13,840
|
13,621
|
10,686
|
10,204
|
14,761
|
14,012
|
|
Intangibles |
7,086
|
6,923
|
6,961
|
6,724
|
6,089
|
10,982
|
|
Total Liabilities |
14,092
|
13,812
|
14,077
|
13,077
|
12,933
|
12,567
|
|
Total Current Liabilities |
2,476
|
2,372
|
4,891
|
3,068
|
2,711
|
2,399
|
|
Long Term Debt |
11,616
|
11,440
|
9,186
|
10,010
|
10,222
|
10,167
|
|
Shareholder equity |
1,384
|
2,133
|
3,703
|
4,690
|
4,648
|
4,871
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
1,979
|
2,072
|
1,772
|
1,913
|
1,972
|
1,557
|
|
Depreciation |
630
|
615
|
591
|
777
|
720
|
638
|
|
Cash from Investing |
-825
|
2,995
|
-1,006
|
-1,365
|
-1,202
|
-882
|
|
Capex |
675
|
767
|
987
|
905
|
829
|
708
|
|
Cash from Financing |
-1,847
|
-4,696
|
-625
|
-766
|
-1,352
|
-139
|
|
Stock Issued |
-1,459
|
-2,372
|
-1,148
|
-782
|
-1,074
|
-524
|
|
Debt (LT) Issued |
-64
|
-1,995
|
700
|
155
|
-125
|
543
|
|
Free Cash Flow |
1,652
|
-2,912
|
2,089
|
1,383
|
1,686
|
82
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
6.7%
|
7.1%
|
1.4%
|
6.1%
|
8.2%
|
2.7%
|
|
NCFO / Op.Income |
118.7%
|
127.1%
|
115.8%
|
105.0%
|
98.0%
|
138.7%
|
|
Current Ratio |
1.3
|
1.6
|
1.7
|
2.9
|
1.5
|
1.9
|
|
Financial Leverage D/E |
8.09
|
5.24
|
2.73
|
1.99
|
1.96
|
1.87
|
|
Return on Capital Avg |
7.1%
|
3.7%
|
4.6%
|
6.9%
|
1.1%
|
5.0%
|
|
Return on Shareholder Equity |
44.0%
|
27.8%
|
3.8%
|
14.2%
|
18.5%
|
5.4%
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available